NCT04739358 2023-10-18CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCCriterium, Inc.Phase 1/2 Terminated2 enrolled
NCT04515394 2022-12-22Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)EMD SeronoPhase 2 Terminated3 enrolled 6 charts